Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Fury Gold Mines Limited (TSX and NYSE American: FURY) ("Fury” or the "Company”) announces that the proposed private placement ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

The VeriTac-2 trial assessed vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2* ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.